The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | Mass spectrometry and response monitoring in multiple myeloma
David Murray, MD, PhD, Mayo Clinic, Rochester, MN, outlines the use of mass spectrometry for the detection of monoclonal proteins (M-proteins) in multiple myeloma and related disorders. Electrophoretic detection has previously been used, however mass spectrometry has demonstrated superior sensitivity and is able to detect lower levels of disease. This method of detection has identified that patients with monoclonal immunoglobulin M-proteins with light chain glycosylation progress onto plasma cell disorders at a higher rate than those who do not. Prof. Murray also discusses how the use of monoclonal antibody therapies can cause interference with electrophoretic detection, and describes how mass spectrometry can overcome some of these interferences. Finally, Prof. Murray talks about the potential of developing a serum-based method for detection of measurable residual disease (MRD) using mass spectrometry. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
David Murray, MD, PhD, discloses potential royalties from intellectual property rights for the use of mass spectroscopy, issued to the Mayo Clinic and licensed to the Binding site.
